New Two-Target drug enters human testing for painful skin condition
NCT ID NCT06895499
Summary
This early-stage study is testing a new drug called HB0043 in adults with moderate to severe hidradenitis suppurativa (HS), a painful chronic skin condition. The main goal is to check the drug's safety and see if it can reduce the number of painful skin lesions. Participants will receive the drug for 20 weeks, followed by a safety check-up period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.